Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study - Weber, M; Kersting, D; Riemann, B (Clin Cancer Res, 2022)
et al.